BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announces the constructing of its new vivarium, an animal research facility, located at BrainStorm's headquarters in Petach-Tikva, Israel.
BrainStorm is working enthusiastically on developing a new treatment for Parkinson’s and ALS diseases. The vivarium will allow Brainstorm to conduct the pre-clinical experiments in-house, including those required by the FDA, thus moving the Company’s research more rapidly towards an FDA Pre-IND submission.
“The addition of this vivarium is a significant step for BrainStorm, this will, with G-Ds' help, accelerate our preclinical studies and enhance the process of a Pre-IND submission to the FDA,” said Chaim Lebovits, BrainStorm’s President. “The vivarium will allow us to conduct several studies in parallel, which will bring us closer to approval of BrainStorm’s life-saving technology within the general marketplace."
The vivarium is built according to highest standards that follow the National Institute of Health’s guidelines. Because the proper management of laboratory animals is essential to the animals’ welfare and the validity of the research data, the animals will be maintained in accordance with the National Research Council guidelines. The vivarium constructed as a clean room to preserve the purity of BrainStorm cells. Once completed, BrainStorm’s scientists will use state of the art equipment, to evaluate the beneficial effects of the Company’s proprietary stem-cell treatment in-vivo.
The facilities will be managed by a certified Veterinarian. All of the employees engaged in these facilities have been suitably trained and are qualified to ensure that the animals receive the proper care and humane treatment. Brainstorm’s animal research center will obtain the required certifications both for the facility as well as for the animal experiments from the Israeli Committee for Animal Research.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The NurOwn(TM) patent pending technology is based on discoveries made by the scientific team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's initial focus is on Parkinson's disease, although its technology has promise for treating several others diseases including MS, ALS, Huntington's disease and stroke.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including BrainStorm's ability to complete its equity financing transactions previously disclosed. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; dependence on its license to Ramot's technology; ability, together with its licensor, to adequately protect the NurOwn(tm) technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.
for BrainStorm Cell Therapeutics Inc.
Juda Englemayer, 212-999-5585
jenglemayer@5wpr.com